3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
7
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
926
Neoplasms
609
Breast Neoplasms
604
Colorectal Neoplasms
457
Neoplasm Metastasis
394
Ovarian Neoplasms
328
Melanoma
312
Prostatic Neoplasms
311
Lung Neoplasms
294
Multiple Myeloma
290
Recurrence
278
Squamous Cell Carcinoma of Head and Neck
246
Stomach Neoplasms
229
Pancreatic Neoplasms
228
Leukemia, Myeloid, Acute
220
Triple Negative Breast Neoplasms
190
Endometrial Neoplasms
190
Carcinoma, Renal Cell
182
Lymphoma, Non-Hodgkin
179
Carcinoma, Hepatocellular
177
Small Cell Lung Carcinoma
165
Leukemia, Lymphocytic, Chronic, B-Cell
156
Advanced Solid Tumors
154
Lymphoma, Follicular
148
Urinary Bladder Neoplasms
139
Lymphoma, Large B-Cell, Diffuse
138
Lymphoma
137
Advanced Solid Tumor
137
Uterine Cervical Neoplasms
134
Head and Neck Neoplasms
134
Interventions
atezolizumab
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Fatty Liver
×
1 year
×
Clear all
NCT06096779
2026-06-01
Kirros
Genentech, Inc.
Phase 2
Recruiting
30 enrolled